

**Synonym**

TNFRSF9,4-1BB,CD137,CDw137,ILA

**Source**

Biotinylated Human 4-1BB, Fc,Avitag(41B-H82F8) is expressed from human 293 cells (HEK293). It contains AA Leu 24 - Gln 186 (Accession # [Q07011-1](#)).

Predicted N-terminus: Leu 24

**Molecular Characterization**

4-1BB(Leu 24 - Gln 186) Q07011-1	Fc(Pro 100 - Lys 330) P01857	Avi
-------------------------------------	---------------------------------	-----

This protein carries a human IgG1 Fc tag at the C-terminus, followed by an Avi tag (Avitag™)

The protein has a calculated MW of 45.4 kDa. The protein migrates as 55-60 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

**Labeling**

*Biotinylation of this product is performed using Avitag™ technology. Briefly, the single lysine residue in the Avitag is enzymatically labeled with biotin.*

**Protein Ratio**

Passed as determined by the HABA assay / binding ELISA.

**Endotoxin**

Less than 0.01 EU per µg by the LAL method.

**Purity**

>95% as determined by SDS-PAGE.

>90% as determined by SEC-MALS.

**Formulation**

Lyophilized from 0.22 µm filtered solution in 50 mM Tris, 100 mM Glycine, 25 mM Arginine, 150 mM NaCl, pH 7.5 with trehalose as protectant.

Contact us for customized product form or formulation.

**Reconstitution**

Please see Certificate of Analysis for specific instructions.

*For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.*


**Storage**

For long term storage, the product should be stored at lyophilized state at -20°C or lower.


*Please avoid repeated freeze-thaw cycles.*

This product is stable after storage at:

- -20°C to -70°C for 12 months in lyophilized state;
- -70°C for 3 months under sterile conditions after reconstitution.



**SDS-PAGE**

Biotinylated Human 4-1BB, Fc,Avitag on SDS-PAGE under reducing (R) condition. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 95%.

**Bioactivity-ELISA****SEC-MALS**

The purity of Biotinylated Human 4-1BB, Fc,Avitag (Cat. No. 41B-H82F8) is more than 90% and the molecular weight of this protein is around 98-120 kDa verified by SEC-MALS.


[Report](#)



Immobilized Biotinylated Human 4-1BB, Fc,Avitag (Cat. No. 41B-H82F8) at 1 µg/mL (100 µL/well) on streptavidin (Cat. No. STN-N5116) precoated (0.5 µg/well) plate can bind UreluMab, Human IgG4 with a linear range of 0.1-6 ng/mL (QC tested).

Immobilized Human 4-1BB Ligand, Mouse IgG2a Fc Tag, low endotoxin (Cat. No. 41L-H5254) at 2 µg/mL (100 µL/well) can bind Biotinylated Human 4-1BB, Fc,Avitag (Cat. No. 41B-H82F8) with a linear range of 0.2-3 ng/mL (Routinely tested).

**Bioactivity-FACS**



FACS assay shows that Biotinylated Human 4-1BB, Fc,Avitag (41B-H82F8) can bind to HEK293/Human 4-1BB Ligand / TNFSF9 Stable Cell Line (CHEK-ATP039). The concentration of Biotinylated Human 4-1BB, Fc,Avitag (41B-H82F8) used is 10 µg/mL (Routinely tested).

**Background**

4-1BB is also known as CD137, tumor necrosis factor receptor superfamily member 9 (TNFRSF9), induced by lymphocyte activation (ILA), is a co-stimulatory molecule of the tumor necrosis factor (TNF) receptor superfamily. CD137 can be expressed by activated T cells, but to a larger extent on CD8 than on CD4 T cells. In addition, CD137 expression is found on dendritic cells, follicular dendritic cells, natural killer cells, granulocytes and cells of blood vessel walls at sites of inflammation. The best characterized activity of CD137 is its costimulatory activity for activated T cells. Crosslinking of CD137 enhances T cell proliferation, IL-2 secretion survival and cytolytic activity. Further, it can enhance immune activity to eliminate tumors in mice. CD137 can enhance activation-induced T cell apoptosis when triggered by engagement of the TCR/CD3 complex. In addition, 4-1BB/4-1BBL co-stimulatory pathway has been shown to augment secondary CTL responses to several viruses, and meanwhile augment anti-tumor immunity. 4-1BB thus is a promising candidate for immunotherapy of human cancer. CD137 has been shown to interact with TRAF2.

**Clinical and Translational Updates**

Please contact us via [TechSupport@acrobiosystems.com](mailto:TechSupport@acrobiosystems.com) if you have any question on this product.